Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
about
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Current therapy of myelodysplastic syndromesCombination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesAllelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AMLCytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.Molecular pathophysiology of myelodysplastic syndromes.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemiaLimited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.Lenalidomide as a novel treatment of acute myeloid leukemia.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Asthma and risk of myelodysplastic syndromes: a population-based cohort study.Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.Trial Watch: Lenalidomide-based immunochemotherapy.Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AMLAcute myeloid leukemia
P2860
Q33574178-4D6B6F33-9942-42F7-9C67-6820AFEB12B1Q34013796-028307FF-7C5E-4B3A-9DC0-3A7BF0CF7613Q34342944-878099AB-F06B-47EC-BF6D-568B2B3D1D7AQ34783754-DCFB3DAC-1410-4198-A328-1B2D018E7697Q35651714-CEE199D2-F657-406B-A7E8-986B95D966F0Q35881223-202B1BD6-F9F9-4A8A-B1AE-7C0A972E5F30Q36445968-E477B76F-2650-4BEB-BC44-1CF1C7D7A04EQ36612675-B4A0B2D8-054C-4BA3-AD87-F093DF2F0D56Q37074311-F9E0DA89-AADF-497F-A5D2-2421722BB1EDQ37299309-175214BA-2A1D-44BE-A8EB-4329FAD4410CQ37679282-597CA1C6-662B-420B-9469-41F237571D84Q38073811-A0C9A865-4B86-454E-BE35-F49EFFA7D221Q38110935-45BD2FF9-9163-4238-B659-A5AD92005A05Q38195796-38DBF9BE-3C1D-403F-9B3B-E92920232127Q38715267-6F896C02-5A41-47EF-8620-77D17CE932A9Q38758162-0991DD36-5465-43AC-91C0-296FBCA0DFEFQ40451190-AF0B580D-BFCC-4D9C-98FD-CEF592761E97Q41764055-1A909F0B-B25C-4679-B0F0-E1801F6075FFQ42285087-661871E6-544F-44AC-A9F6-DCDCCD9C1A4BQ42323676-F05C2F60-C08F-4CA8-B424-481854AA53FBQ42737828-397F3294-713F-424E-99A8-305B425A680CQ43134067-083DDF43-0A15-4708-900D-3B2FED5A12EBQ54204985-1BDAE749-C432-4A52-83D5-5022C9700591Q57927278-F1321433-343E-4D81-9E49-28B9BBDACEF8Q58481761-54658700-4825-431A-98EB-33B8E4A44980
P2860
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@ast
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@en
type
label
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@ast
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@en
prefLabel
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@ast
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@en
P2093
P2860
P50
P1433
P1476
Clinical effect of increasing ...... th chromosome 5 abnormalities.
@en
P2093
Anna Porwit
Elisabeth Ejerblad
Eva Hellström-Lindberg
Hanne Vestergaard
Hege Garelius
Inge Høgh Dufva
Ingunn Dybedal
Jan Astermark
Jan Maxwell Nørgaard
Kirsten Grønbæk
P2860
P304
P356
10.3324/HAEMATOL.2010.039669
P577
2011-07-01T00:00:00Z